Skip to main content
Journal Article

Cannabidiol for people with schizophrenia

Cochrane Database of Systematic Reviews (2022) 2022(11)
DOI: 10.1002/14651858.CD014602
0Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of CBD in the treatment of people with schizophrenia.

Cite

CITATION STYLE

APA

Buitrago-Garcia, D., Sánchez Vanegas, G., Sánchez Correa, P. A., Baracaldo, S. del pilar, Gallego Gallego, S. F., & Baandrup, L. (2022). Cannabidiol for people with schizophrenia. Cochrane Database of Systematic Reviews, 2022(11). https://doi.org/10.1002/14651858.CD014602

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free